Literature DB >> 15929203

Risk of thromboembolism in patients with idiopathic autoimmune hemolytic disease and antiphospholipid antibodies: results from a prospective, case-control study.

Velia Bongarzoni, Luciana Annino, Andrea Roveda, Maria Antonietta Amendolea, Maria Cristina Tirindelli, Giuseppe Avvisati.   

Abstract

During a period of 4 years, 21 consecutive patients with newly diagnosed idiopathic autoimmune hemolytic disease (IAHD) and 42 healthy, sex- and age-matched subjects, were tested for the presence of antiphospholipid antibodies (APA). At diagnosis, APA were detected in 10/21 (47.6%) patients and in 2/42 (4.76%) controls (p< 0.01). No thromboembolic events were registered during the follow-up period.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15929203

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  4 in total

Review 1.  Prevalence of secondary hematologic disorders in the antiphospholipid syndrome: impact on coagulation risk.

Authors:  Sharon L Kolasinski
Journal:  Curr Rheumatol Rep       Date:  2006-04       Impact factor: 4.592

Review 2.  Primary thrombosis prophylaxis in antiphospholipid antibody-positive patients: where do we stand?

Authors:  Medha Barbhaiya; Doruk Erkan
Journal:  Curr Rheumatol Rep       Date:  2011-02       Impact factor: 4.592

Review 3.  Antiphospholipid Antibodies and Autoimmune Haemolytic Anaemia: A Systematic Review and Meta-Analysis.

Authors:  Paul R J Ames; Mira Merashli; Tommaso Bucci; Daniele Pastori; Pasquale Pignatelli; Alessia Arcaro; Fabrizio Gentile
Journal:  Int J Mol Sci       Date:  2020-06-09       Impact factor: 5.923

4.  Venous thromboembolic events during warm autoimmune hemolytic anemia.

Authors:  Sylvain Audia; Benoit Bach; Maxime Samson; Daniela Lakomy; Jean-Baptiste Bour; Bénédicte Burlet; Julien Guy; Laurence Duvillard; Marine Branger; Vanessa Leguy-Seguin; Sabine Berthier; Marc Michel; Bernard Bonnotte
Journal:  PLoS One       Date:  2018-11-08       Impact factor: 3.240

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.